This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Henry Szechtman, PhD; Claude Nahmias, PhD; E. Stephen Garnett, MD; Gunther Firnau, PhD; Gregory M. Brown, MD, PhD; Ronald D. Kaplan, PhD; John M. Cleghorn, MD

Arch Gen Psychiatry. 1988;45(6):523-532.

Abstract
• This study examines whether the duration of treatment with antipsychotic drugs influences the regional distribution of cerebral [¹⁸F]2-fluoro-2-deoxy-D-glucose utilization as measured by positron emission tomography. Two groups of schizophrenic patients are compared with normal volunteers (n =10). One group (n = 5) consisted of patients treated for one year, and the second (n=12) of patients medicated for four to 14 years (mean ± SD duration, 7.4±3.4 years). The first group was also examined before patients received their first dose ever of antipsychotic medication. One year of medication was not sufficient to alter the schizophrenic profile of cerebral cortical glucose activity but did elevate activity of the corpus striatum. Medication for 7.4 years also did not alter the schizophrenic pattern of frontal hyperactivity and posterior hypoactivity, although deviations from control values appeared less marked than after one year. On the other hand, in patients medicated for 7.4 years, there was perhaps an even greater increase in the activity of the corpus striatum and of the thalamus. Thus, duration of exposure to antipsychotic medication may affect the pattern of cerebral glucose activity; possibly, even longer exposure may contribute to the hypofrontality noted by others, although this can be confounded with the duration of illness as a factor. In considering the biological significance of the observed profile of cortical glucose activity, we introduce the concept of cerebral metabolic tone. We suggest that a disturbance of this tonus may account for some symptoms of schizophrenia and could be consistent with the hypothesis of abnormal developmental changes in the brains of schizophrenics.

Author Affiliations
From the Departments of Neurosciences (Drs Szechtman and Brown) and Psychiatry (Drs Szechtman, Brown, Kaplan, and Cleghorn), McMaster University, and the Department of Nuclear Medicine, Chedoke-McMaster Hospitals (Drs Nahmias, Garnett, and Firnau), Hamilton, Ontario.

Footnotes
Accepted for publication Dec 14, 1987.

Reprint requests to Department of Neurosciences, McMaster University, 1200 Main St W, Hamilton, Ontario, Canada L8N 3Z5 (Dr Szechtman).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effects of Psychotic State and Task Demand on Prefrontal Function in Schizophrenia: An fMRI Study of Overt Verbal Fluency
Fu et al.
Am. J. Psychiatry 2005;162:485-494.
ABSTRACT | FULL TEXT  

Cerebrovascular Response to Cognitive Tasks and Hyperventilation Measured by Multi-Channel Near-Infrared Spectroscopy
Watanabe et al.
J. Neuropsychiatry Clin. Neurosi. 2003;15:442-449.
ABSTRACT | FULL TEXT  

Functional brain mapping of psychopathology
Honey et al.
J. Neurol. Neurosurg. Psychiatry 2002;72:432-439.
ABSTRACT | FULL TEXT  

Three-Dimensional Analysis With MRI and PET of the Size, Shape, and Function of the Thalamus in the Schizophrenia Spectrum
Hazlett et al.
Am. J. Psychiatry 1999;156:1190-1199.
ABSTRACT | FULL TEXT  

Decreased Caudate Volume in Neuroleptic-Naive Psychotic Patients
Keshavan et al.
Am. J. Psychiatry 1998;155:774-778.
ABSTRACT | FULL TEXT  

Cerebral Blood Flow Velocity in Acute Schizophrenic Patients : A Transcranial Doppler Ultrasonography Study
Owega et al.
Stroke 1998;29:1149-1154.
ABSTRACT | FULL TEXT  

Decline of Dopamine: Effects of Age and Acute Neuroleptic Challenge
Am. J. Psychiatry 1998;155:319-323.
FULL TEXT  

Dorsal Striatal Size, Shape, and Metabolic Rate in Never-Medicated and Previously Medicated Schizophrenics Performing a Verbal Learning Task
Shihabuddin et al.
Arch Gen Psychiatry 1998;55:235-243.
ABSTRACT | FULL TEXT  

The Brain Metabolic Patterns of Clozapine- and Fluphenazine-Treated Patients With Schizophrenia During a Continuous Performance Task
Cohen et al.
Arch Gen Psychiatry 1997;54:481-486.
ABSTRACT  

Frontostriatal Disorder of Cerebral Metabolism in Never-Medicated Schizophrenics
Buchsbaum et al.
Arch Gen Psychiatry 1992;49:935-942.
ABSTRACT  

Hypofrontality in Neuroleptic-Naive Patients and in Patients With Chronic Schizophrenia: Assessment With Xenon 133 Single-Photon Emission Computed Tomography and the Tower of London
Andreasen et al.
Arch Gen Psychiatry 1992;49:943-958.
ABSTRACT  

Striatal Metabolic Rate and Clinical Response to Neuroleptics in Schizophrenia
Buchsbaum et al.
Arch Gen Psychiatry 1992;49:966-974.
ABSTRACT  

Limbic System Abnormalities Identified in Schizophrenia Using Positron Emission Tomography With Fluorodeoxyglucose and Neocortical Alterations With Deficit Syndrome
Tamminga et al.
Arch Gen Psychiatry 1992;49:522-530.
ABSTRACT  

Altered Modulation of Prefrontal and Subcortical Brain Activity in Newly Diagnosed Schizophrenia and Schizophreniform Disorder: A Regional Cerebral Blood Flow Study
Rubin et al.
Arch Gen Psychiatry 1991;48:987-995.
ABSTRACT  

Magnetic Resonance Imaging Abnormalities in Lenticular Nuclei and Cerebral Cortex in Schizophrenia
Jernigan et al.
Arch Gen Psychiatry 1991;48:881-890.
ABSTRACT  

Morphine-Induced Metabolic Changes in Human Brain: Studies With Positron Emission Tomography and [Fluorine 18]Fluorodeoxyglucose
London et al.
Arch Gen Psychiatry 1990;47:73-81.
ABSTRACT  

Inferior Parietal Region Implicated in Neurocognitive Impairment in Schizophrenia
Cleghorn et al.
Arch Gen Psychiatry 1989;46:758-759.
ABSTRACT